Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Residual Disease”

474 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 474 results

Not applicableLooking for participantsNCT06697483
What this trial is testing

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 100
Early research (Phase 1)Active Not RecruitingNCT03233854
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more
Stanford University 56
Testing effectiveness (Phase 2)Active Not RecruitingNCT03376672
What this trial is testing

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Who this might be right for
Multiple Myeloma
Raija Silvennoinen 120
Not applicableNot Yet RecruitingNCT07254156
What this trial is testing

Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer

Who this might be right for
Colorectal CancerMRDctDNA
Sun Yat-sen University 229
Large-scale testing (Phase 3)Study completedNCT04642469
What this trial is testing

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Who this might be right for
Carcinoma, Non- Small Cell Lung
AstraZeneca 30
Testing effectiveness (Phase 2)Looking for participantsNCT05536505
What this trial is testing

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Who this might be right for
MRD
Guangdong Association of Clinical Trials 180
Not applicableUnknownNCT06182917
What this trial is testing

Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients

Who this might be right for
Ovarian Cancer
West China Second University Hospital 35
Not applicableNot Yet RecruitingNCT07443592
What this trial is testing

Treatment for Ph-negative ALL for Adults up to 65 Years

Who this might be right for
Acute Lymphoblastic Leukemia
PETHEMA Foundation 330
Not applicableLooking for participantsNCT06963307
What this trial is testing

Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
JaxBio Ltd 300
Testing effectiveness (Phase 2)Looking for participantsNCT04966663
What this trial is testing

Using ctDNA to Determine Therapies for Lung Cancer

Who this might be right for
Non Small Cell Lung CancerComplete Surgical ResectionCirculating Tumor DNA
University Health Network, Toronto 66
Not applicableLooking for participantsNCT05704530
What this trial is testing

Liquid Biopsies in Esophageal Cancer

Who this might be right for
Esophageal Cancer
Universitaire Ziekenhuizen KU Leuven 248
Not applicableStudy completedNCT01078337
What this trial is testing

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

Who this might be right for
Leukemia, Lymphocytic, Acute
Stanford University 15
Not applicableEnded earlyNCT03549351
What this trial is testing

Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Who this might be right for
Leukemia, Myeloid, Acute
University Hospital Heidelberg 51
Not applicableStudy completedNCT01498302
What this trial is testing

Comparison of Laboratory Test Results of Minimal-Residual Disease in Samples From Patients With Acute Myeloid Leukemia

Who this might be right for
Leukemia
Children's Oncology Group 10
Early research (Phase 1)WithdrawnNCT02786485
What this trial is testing

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Who this might be right for
LeukemiaMyelodysplastic SyndromesLymphomas+2 more
Bellicum Pharmaceuticals
Not applicableLooking for participantsNCT06693830
What this trial is testing

CtDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Who this might be right for
LymphomaLymphoma, B-CellDiffuse Large B Cell Lymphoma+2 more
Hua-Jay J Cherng, MD 40
Early research (Phase 1)Active Not RecruitingNCT06358430
What this trial is testing

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Who this might be right for
Colorectal CancerMinimal Residual Disease
M.D. Anderson Cancer Center 10
Testing effectiveness (Phase 2)Looking for participantsNCT06426511
What this trial is testing

CtDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 80
Not applicableStudy completedNCT06525116
What this trial is testing

MRD Detection by NGS in Pediatric T-ALL

Who this might be right for
Acute Lymphoblastic Leukemia, Pediatric
The Children's Hospital of Zhejiang University School of Medicine 148
Testing effectiveness (Phase 2)Study completedNCT00358072
What this trial is testing

Treatment of Adult ALL With an MRD-directed Programme.

Who this might be right for
Acute Lymphoblastic Leukemia
Northern Italy Leukemia Group 280
Next Page